Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects

被引:20
作者
Zhou, XJ [1 ]
Lloyd, DM [1 ]
Chao, GC [1 ]
Brown, NA [1 ]
机构
[1] Idenix Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
telbivudine; hepatitis B; antiviral; pharmacokinetics; food effect;
D O I
10.1177/0091270005284849
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of food on the pharmocokinetics of telbivudine, a candidate antiviral agent against hepatitis B virus (HBV), was investigated in healthy adult following a 600-mg oral dose administered with and without a high-fat/high-calorie meal. Telbivudine was well tolerated under fasting and fed conditions. Oral absorption of telbivudine as measured by maximum plasma concentration (C-max), time to reach C-max (T-max) and area under the plasma concentration-time curve (AUC(0-t) and AUC(0-infinity)) was not altered by food intake immediately before oral dosing. Values of C-max, T-max, and AUC were comparable when telbivudine was administered Underfed and fasting conditions. Results from this study indicated that the absorption of telbivudine was not affected by a high-fat/high-calorie meal; telbivudine can therefore be administered orally with no regard to the timing of meals.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 23 条
  • [1] PHARMACOKINETICS OF 3TC (GR109714X) ADMINISTERED WITH AND WITHOUT FOOD TO HIV-INFECTED PATIENTS
    ANGEL, JB
    HUSSEY, EK
    HALL, ST
    DONN, KH
    MORRIS, DM
    MCCORMACK, JP
    MONTANER, JSG
    RUEDY, J
    [J]. DRUG INVESTIGATION, 1993, 6 (02): : 70 - 74
  • [2] Bridges EG, 2003, FRONTIERS IN VIRAL HEPATITIS, P263, DOI 10.1016/B978-044450986-4/50073-4
  • [3] BRIDGES EG, 2001, ANTIVIR RES, P84
  • [4] Bryant M., 1999, ANTIVIR THER, V4, pA124
  • [5] Antiviral L-nucleosides specific for hepatitis B virus infection
    Bryant, ML
    Bridges, EG
    Placidi, L
    Faraj, A
    Loi, AG
    Pierra, C
    Dukhan, D
    Gosselin, G
    Imbach, JL
    Hernandez, B
    Juodawlkis, A
    Tennant, B
    Korba, B
    Cote, P
    Marion, P
    Cretton-Scott, E
    Schinazi, RF
    Sommadossi, JP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 229 - 235
  • [6] Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food
    Chittick, GE
    Gillotin, C
    McDowell, JA
    Lou, Y
    Edwards, KD
    Prince, WT
    Stein, DS
    [J]. PHARMACOTHERAPY, 1999, 19 (08): : 932 - 942
  • [7] Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads
    Damle, BD
    Yan, JH
    Behr, D
    O'Mara, E
    Nichola, P
    Kaul, S
    Knupp, C
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04) : 419 - 427
  • [8] COST-EFFECTIVENESS OF ONCE-DAILY ORAL ANTIMICROBIAL THERAPY
    DAVEY, P
    PARKER, S
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (08) : 706 - 710
  • [9] Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes:: Relevance to chemotherapeutic efficacy against hepatitis B virus
    Hernandez-Santiago, B
    Placidi, L
    Cretton-Scott, E
    Faraj, A
    Bridges, EG
    Bryant, ML
    Rodriguez-Orengo, J
    Imbach, JL
    Gosselin, G
    Pierra, C
    Dukhan, D
    Sommadossi, JP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) : 1728 - 1733
  • [10] Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection
    Kaul, S
    Christofalo, B
    Raymond, RH
    Stewart, MB
    Macleod, CM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2295 - 2298